Attached files

file filename
EX-1.1 - EX-1.1 - Teladoc Health, Inc.a17-27913_1ex1d1.htm
8-K - 8-K - Teladoc Health, Inc.a17-27913_18k.htm

Exhibit 5.1

 

GRAPHIC

555 Eleventh Street, N.W., Suite 1000

Washington, D.C.  20004-1304

Tel: +1.202.637.2200  Fax: +1.202.637.2201

www.lw.com

FIRM / AFFILIATE OFFICES

 

Barcelona

Moscow

 

Beijing

Munich

 

Boston

New York

 

Brussels

Orange County

December 4, 2017

Century City

Paris

Chicago

Riyadh

Dubai

Rome

 

Düsseldorf

San Diego

 

Frankfurt

San Francisco

 

Hamburg

Seoul

 

Hong Kong

Shanghai

 

Houston

Silicon Valley

 

London

Singapore

 

Los Angeles

Tokyo

 

Madrid

Washington, D.C.

 

Milan

 

 

Teladoc, Inc.

2 Manhattanville Road, Suite 203

Purchase, NY 10577

 

Re:         Registration Statement No. 333-221784 on Form S-3; Public Offering of Shares of Common Stock of Teladoc, Inc.

 

Ladies and Gentlemen:

 

We have acted as special counsel to Teladoc, Inc., a Delaware corporation (the “Company”), in connection with the issuance of 4,096,600 shares (the “Company Shares”) of the Company’s common stock, $0.001 par value per share (“Common Stock”), by the Company and the sale of 830,000 shares (the “Selling Stockholder Shares” and, together with the Company Shares, the “Shares”) of Common Stock by certain stockholders of the Company. The Shares are included in a registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on November 28, 2017 (Registration No. 333-221784) (as so filed and as amended, the “Registration Statement”), including a base prospectus dated November 28, 2017 (the “Base Prospectus”) and a prospectus supplement dated November 29, 2017 (together with the Base Prospectus, the “Prospectus”), and were sold pursuant to an underwriting agreement, dated November 29, 2017, among the Company, the selling stockholders named therein and J.P. Morgan Securities LLC, as representative of the several underwriters named therein (the “Underwriting Agreement”).

 

This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as expressly stated herein with respect to the issue of the Shares.

 

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the

 



 

December 4, 2017

Page 2

 

 

GRAPHIC

 

General Corporation Law of the State of Delaware and we express no opinion with respect to the applicability thereto, or the effect thereon, of the laws of any other jurisdiction or, in the case of Delaware, any other laws, or as to any matters of municipal law or the laws of any local agencies within any state.

 

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, the Company Shares have been duly authorized by all necessary corporate action of the Company and, when the Company Shares have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Underwriting Agreement, the Company Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware.

 

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company’s Form 8-K dated December 5, 2017 and to the reference to our firm contained in the Prospectus under the heading “Legal Matters.” In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

 

 

Very truly yours,

 

 

 

/s/ Latham & Watkins LLP